Ammoxetine hydrochloride - CSPC Zhongqi Pharmaceutical Technology
Alternative Names: Ammuxetine hydrochloride - CSPC ZhongQi Pharmaceutical TechnologyLatest Information Update: 19 Aug 2026
At a glance
- Originator Academy of Military Medical Sciences
- Class Analgesics; Antidepressants; Anxiolytics; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 15 Jul 2026 CSPC ZhongQi Pharmaceutical Technology initiates enrolment in a phase I trial for Healthy volunteers in China (PO) (NCT07756996)
- 10 May 2026 CSPC ZhongQi Pharmaceutical Technology initiated a phase I pharmacokinetic trial in Healthy volunteers in China (PO, Tablet) (NCT07694869)
- 30 Mar 2026 CSPC ZhongQi Pharmaceutical Technology initiates enrolment in a phase I Pharmacokinetic trial in China (PO)(NCT07694843)